spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Systemic Lupus Erythematosus 

 HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 20 Dec 2021
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 30 Sep 2021
OLUMIANT(R) Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata
Biopharmaceuticals
 HSMN NewsFeed - 26 Aug 2021
FDA Clears Thermo Scientific EliA SmD(P)-S Test For Use In U.S.
Diagnostics FDA
 HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 19 Jan 2021
Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2020
Athos Therapeutics Announces Appointment of Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Dec 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Biopharmaceuticals
 HSMN NewsFeed - 8 Mar 2018
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 11 May 2017
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Apr 2017
Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Apr 2017
U.S. FDA Issues Complete Response Letter for Baricitinib
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Feb 2017
European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jan 2017
Celgene to Acquire Delinia, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Dec 2016
Neovacs obtains FDA “Fast Track” designation for IFNα Kinoid in Lupus (SLE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Nov 2016
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar(R) Gel for Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2016
Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2016
Padlock Therapeutics Creates West Coast Operations Appointing Scientific Co-founder Kerri Mowen, Ph.D., as Director of Biology Based in San Diego
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2014
Lilly to Discontinue Development of Tabalumab Based on Efficacy Results in Phase 3 Lupus Studies
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2013
Exagen Diagnostics Appoints New Board Member
Diagnostics Personnel
 HSMN NewsFeed - 1 Oct 2012
XDx Appoints Peter Maag as President and CEO
Diagnostics Personnel
 HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jun 2011
Sheila Gujrathi, M.D. Named Chief Medical Officer of Receptos
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 May 2011
GlaxoSmithKline and Human Genome Sciences Receive Positive Opinion in Europe from the CHMP for BENLYSTA(R) (Belimumab)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Oct 2010
FDA Approves H.P. Acthar(R) Gel for the Treatment of Infantile Spasms
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 19 Aug 2010
Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for BENLYSTA(R) (belimumab) as a Potential Treatment for Systemic Lupus Erythematosus
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Aug 2010
Human Genome Sciences Names Tuomo Pätsi Vice President, HGS Europe
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2010
New Data Presented from EMBLEM Study for Pipeline Drug Epratuzumab for Patients Suffering from Moderate to Severe Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 10 Jun 2010
Human Genome Sciences Announces Submission of Biologics License Application to FDA for BENLYSTA(R) (belimumab)
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2010
Human Genome Sciences Announces Submission of Marketing Authorization Application to EMA for BENLYSTA(R) (Belimumab)
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2010
Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2010
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 2 Nov 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2009
Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2009
XDx Completes $14.4 Million Series G Financing
Diagnostics Venture Capital
 HSMN NewsFeed - 20 Jul 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals
 HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2009
Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Feb 2009
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Biopharmaceuticals
 HSMN NewsFeed - 26 Jan 2009
Sequenom Expands Molecular Diagnostics Portfolio with Acquisition of SensiGen
Diagnostics Acquisitions
 HSMN NewsFeed - 24 Nov 2008
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jun 2008
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2008
New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2008
Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
Diagnostics FDA
 HSMN NewsFeed - 27 Mar 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Mar 2008
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Program; Announces Fourth Quarter and Year-End 2007 Financial Results
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2008
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2008
Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2007
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve BP Goals
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 16 Nov 2007
Argos Therapeutics and Therakos, Inc. Enter Exclusive Agreement for Regulatory T Cell Technology
Biopharmaceuticals Licensing
 HSMN NewsFeed - 15 Nov 2007
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Nov 2007
Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2007
ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Sep 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Sep 2007
Teva Provides Update on Edratide for Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2007
Aspreva Provides Update On Lupus Nephritis Development Program
Biopharmaceuticals
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Jul 2007
Corgenix Submits 510(k) Filing for IgG Anti-AtherOx(TM) Test Kit
Diagnostics FDA
 HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Biopharmaceuticals
 HSMN NewsFeed - 25 Jun 2007
PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jun 2007
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2007
Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2007
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 May 2007
Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2007
La Jolla Pharmaceutical Company Reports Riquent(R) Well Tolerated in Three Studies at International Lupus Congress
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 May 2007
Bayhill Therapeutics Appoints Fred Kurland as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2007
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Apr 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 5 Apr 2007
PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Mar 2007
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 8 Mar 2007
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2007
Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2007
La Jolla Pharmaceutical Announces Continued Enrollment Progress and Enhancements to International Phase 3 Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2007
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference
Biopharmaceuticals
 HSMN NewsFeed - 4 Dec 2006
Bayhill Therapeutics Names Paul Westberg Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2006
Bayhill Therapeutics Names Robert S. King Vice President of Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2006
Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2006
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Oct 2006
La Jolla Pharmaceutical Provides Update on MAA Application in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Sep 2006
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 28 Aug 2006
Genentech and Biogen Idec Announce Positive Results From a Phase II Trial of Rituxan in Relapsing-Remitting Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 Aug 2006
La Jolla Pharmaceutical Expands Enrollment in Phase 3 International Riquent(R) Study
Biopharmaceuticals
 HSMN NewsFeed - 9 Aug 2006
Human Genome Sciences Announces Phase 3 Clinical Development Program for LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2006
Michael Tansey, M.D. Joins La Jolla Pharmaceutical Company as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 22 Jun 2006
La Jolla Pharmaceutical Company Files Marketing Authorization Application for European Regulatory Approval of Riquent
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jun 2006
Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2006
UCB and Immunomedics announce worldwide development collaboration and license agreement for Epratuzumab
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 Apr 2006
EU Label Change for INTRON(R) A (interferon Alfa-2b) Incorporates Long-Term Efficacy Data in Patients with Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2006
Epratuzumab for Immunotherapy of Lupus Results Published
Biopharmaceuticals
 HSMN NewsFeed - 30 Mar 2006
Genentech and Biogen Idec Submit Supplemental Biologics License Application for First-Line Use of Rituxan(R) in Low-Grade or Follicular CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Mar 2006
La Jolla Pharmaceutical Announces Appointment of Deirdre Y. Gillespie as New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2006
African American Heart Failure Trial Shows Women and Men Both Benefit from BiDil(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Mar 2006
Researchers Identify Gene Variations That May Determine Which Heart Failure Patients Are Likely to Benefit from Treatment With BiDil(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Feb 2006
FDA Approves Rituxan(R) - The First Targeted B-Cell Therapy for Treatment of Moderate-to-Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2006
Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jan 2006
Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  

 Additional items found! 73

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 73 additional stories matching:
Systemic Lupus Erythematosus
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.